Norepinephrine

Norepinephrine, also called noradrenaline, is a catecholamine that functions as a neurotransmitter, neuromodulator, and hormone. It is the principal transmitter released by most postganglionic sympathetic neurons and is also produced by neurons in the brain and by chromaffin cells of the adrenal medulla. Chemically related to dopamine and epinephrine, it acts through adrenergic receptors to influence the activity of target cells. (pubchem.ncbi.nlm.nih.gov)

Norepinephrine connects neural signaling with the regulation of circulation, alertness, attention, and responses to stress. Its effects depend on the receptors and tissues involved: peripheral actions include vascular constriction and cardiac stimulation, while central actions modulate arousal and information processing. Its synthesis, storage, release, reuptake, and metabolism provide multiple points of physiological control and pharmacological intervention. (ncbi.nlm.nih.gov)

As a medicine, norepinephrine is administered intravenously to raise blood pressure in acute hypotensive states. Its medical use is distinct from its locally regulated actions as an endogenous transmitter and requires attention to circulatory effects and adverse reactions. Research on norepinephrine also helped establish fundamental principles of chemical neurotransmission, including vesicular storage and neuronal reuptake. (dailymed.nlm.nih.gov)

Chemical identity and nomenclature

Norepinephrine and noradrenaline, commonly abbreviated NE and NA, are alternative names for the same chemical substance, not different transmitters or different stereochemical forms. Other names include levarterenol and arterenol. The endogenous compound functions as a neurotransmitter and hormone; these terms describe biological roles rather than distinct molecular identities. Its systematic name is 4-[(1R)-2-amino-1-hydroxyethyl]benzene-1,2-diol, which specifies both the arrangement of its functional groups and the configuration of its asymmetric carbon atom. (pubchem.ncbi.nlm.nih.gov)

Norepinephrine belongs to the catecholamine family. Its catechol component is a benzene ring bearing two adjacent hydroxyl groups; relative to the attached side chain, these occupy the 3 and 4 positions. The two-carbon side chain contains a primary amine, $–\mathrm{NH_2}$, and a β-hydroxyl group on the carbon directly attached to the aromatic ring. Here, “β” identifies the carbon’s position relative to the amine, not a stereochemical orientation. The neutral parent molecule has the formula $\mathrm{C_8H_{11}NO_3}$ and a molar mass of approximately $169.18\ \mathrm{g\,mol^{-1}}$. Its three oxygen atoms therefore comprise two phenolic hydroxyls and one side-chain alcohol group. (pubchem.ncbi.nlm.nih.gov)

The hydroxyl-bearing side-chain carbon is attached to four different groups: hydrogen, hydroxyl, an aminomethyl group, and the substituted aromatic ring. It is consequently a center of chirality. Naturally occurring norepinephrine has the $R$ configuration and is commonly designated $R$-(−)-norepinephrine; the corresponding $S$ form is its mirror-image enantiomer. The $R$ descriptor specifies absolute configuration according to stereochemical sequence rules, whereas the minus sign denotes optical rotation. These are separate kinds of information: an $R$ configuration does not generally imply negative rotation. Likewise, changing between the names “norepinephrine” and “noradrenaline” does not change the compound’s configuration. (pubchem.ncbi.nlm.nih.gov)

Comparison with dopamine and epinephrine identifies two small but chemically important structural differences. Dopamine has the same catechol ring and primary amine but lacks the β-hydroxyl group: its side chain is $–\mathrm{CH_2–CH_2–NH_2}$, rather than norepinephrine’s $–\mathrm{CH(OH)–CH_2–NH_2}$. Dopamine therefore has the formula $\mathrm{C_8H_{11}NO_2}$ and lacks norepinephrine’s side-chain stereocenter. Epinephrine retains the β-hydroxyl group but carries an additional methyl substituent on nitrogen, giving a secondary amine, $–\mathrm{NHCH_3}$, instead of norepinephrine’s primary amine. Epinephrine’s formula is consequently $\mathrm{C_9H_{13}NO_3}$. (pubchem.ncbi.nlm.nih.gov)

The parent molecule must also be distinguished from pharmaceutical salts. Norepinephrine bitartrate monohydrate, for example, contains norepinephrine with a tartrate counterion and water of crystallization; its stated composition is $\mathrm{C_8H_{11}NO_3\cdot C_4H_6O_6\cdot H_2O}$, with a molar mass of $337.28\ \mathrm{g\,mol^{-1}}$. That value describes the complete salt hydrate, not norepinephrine alone. Product labeling may therefore express strength as the equivalent amount of norepinephrine base rather than the total mass of salt. This distinction concerns chemical composition and mass accounting, not a different endogenous transmitter. (dailymed.nlm.nih.gov)

Biosynthesis and intracellular storage

Norepinephrine synthesis begins with the amino acid L-tyrosine. In the cytosol, tyrosine hydroxylase (TH) converts tyrosine to L-3,4-dihydroxyphenylalanine, or L-DOPA. Aromatic L-amino-acid decarboxylase (AADC), also called DOPA decarboxylase, then removes the carboxyl group from L-DOPA, producing dopamine. These reactions occur outside the secretory vesicle, although the enzymes can associate with vesicular membranes: experiments reported in 2009 demonstrated physical and functional interactions between TH, AADC, and the vesicular monoamine transporter VMAT2, linking dopamine production to its packaging. Dopamine subsequently enters secretory vesicles, where dopamine β-hydroxylase (DBH) converts it to norepinephrine. Thus, the pathway crosses a membrane between dopamine formation and norepinephrine formation rather than proceeding entirely within one cellular compartment. (pmc.ncbi.nlm.nih.gov)

TH catalyzes the rate-limiting step of catecholamine biosynthesis and is an important site of metabolic regulation. Its activity depends on the cofactor tetrahydrobiopterin and is inhibited by catecholamine end products, providing negative feedback on further synthesis. Phosphorylation of serine 40 can relieve this inhibition. In experiments published in 2008, Sarah Gordon and colleagues identified two dopamine-binding sites on TH: phosphorylation abolished binding at the high-affinity inhibitory site, whereas a second, lower-affinity site remained functional. This regulation changes enzyme activity without requiring the immediate synthesis of additional enzyme protein. (pubmed.ncbi.nlm.nih.gov)

Vesicular uptake is mediated by vesicular monoamine transporters (VMATs), which exchange cytosolic monoamines for protons moving out of the vesicle. A vesicular proton pump establishes the gradient that supplies the energy for this transport; VMAT therefore uses an existing gradient rather than directly hydrolyzing ATP. Monoamine uptake is coupled to the movement of approximately two protons per transported monoamine. VMAT2 is the principal neuronal isoform, while human adrenal chromaffin cells express both VMAT1 and VMAT2. These transporters package catecholamines into neuronal secretory vesicles and adrenal chromaffin-cell granules, respectively. (pmc.ncbi.nlm.nih.gov)

Inside these organelles, DBH hydroxylates dopamine’s β-carbon to produce norepinephrine. Its location makes vesicular dopamine uptake a prerequisite for this final synthetic step. DBH is a copper-containing enzyme, and ascorbate supplies reducing equivalents needed for its catalytic cycle. Experiments with cultured bovine chromaffin cells and isolated chromaffin vesicles showed that the enzyme’s apparent affinity for ascorbate differs substantially from that measured with purified enzyme: the reported apparent $K_m$ was approximately 15 millimolar in situ, compared with 0.6 millimolar under optimized cell-free conditions. This difference illustrates how the vesicular environment affects synthesis as well as providing a storage compartment. (onlinelibrary.wiley.com)

In cells expressing phenylethanolamine N-methyltransferase (PNMT), norepinephrine becomes a precursor of epinephrine rather than the pathway’s final product. PNMT transfers a methyl group to norepinephrine’s nitrogen. Adrenal PNMT expression and activity are regulated by glucocorticoids, members of the corticosteroid family. Richard Wurtman and Julius Axelrod demonstrated this relationship experimentally in 1965: removal of the pituitary gland markedly reduced adrenal PNMT activity in rats, while administration of adrenocorticotropic hormone or dexamethasone restored activity. Later experiments measuring both PNMT messenger RNA and enzyme activity showed that glucocorticoid regulation involves changes in gene expression but cannot be explained by transcription alone; regulation of enzyme protein stability also contributes. (pubmed.ncbi.nlm.nih.gov)

Anatomical organization of noradrenergic systems

Within the central nervous system, norepinephrine-producing neuronal cell bodies are concentrated in brainstem nuclei rather than distributed uniformly through their target regions. The most prominent group is the paired locus coeruleus (A6), situated in the dorsal pons. Other groups include A1 in the caudal ventrolateral medulla, A2 within the nucleus of the solitary tract, and the pontine A5 and A7 groups. The locus coeruleus is therefore a major source of central noradrenergic innervation, but not its sole source. Tract-tracing and catecholamine-enzyme labeling distinguish these populations and show that medullary groups contribute ascending projections, including substantial inputs to hypothalamic regions. (ncbi.nlm.nih.gov)

Ascending noradrenergic fibers reach the cerebral cortex, hippocampus, amygdala, thalamus, and hypothalamus; descending fibers reach brainstem and spinal cord targets. These destinations are terminal fields, not additional concentrations of noradrenergic cell bodies: a cortical norepinephrine-containing ending can belong to a neuron whose soma lies in the pons. Although locus-coeruleus projections are widespread, their origins are anatomically organized. In a 1986 retrograde-tracing study in rats, hippocampal projections arose from the dorsal segment of the locus coeruleus, whereas spinal projections originated from its ventral-posterior portion. Separate tracing studies demonstrated noradrenergic A1 and A2 projections to the hypothalamus, illustrating that forebrain innervation combines inputs from distinct brainstem populations. (ncbi.nlm.nih.gov)

Spinal noradrenergic innervation likewise has several sources. A study published in 2012 mapped descending projections from A5, A6, and A7 in rats and found different regional emphases: locus-coeruleus fibers preferentially innervated dorsal-horn territories, A7 fibers were particularly associated with ventral-horn motor regions, and A5 supplied a prominent input to the thoracic intermediolateral cell column containing sympathetic preganglionic neurons. These are overlapping projection patterns rather than completely separate channels. They distinguish noradrenergic fibers terminating within spinal neural circuits from peripheral sympathetic axons that subsequently innervate organs. (pubmed.ncbi.nlm.nih.gov)

Outside the central nervous system, most noradrenergic cell bodies belong to sympathetic postganglionic neurons in paravertebral or prevertebral ganglia. Their axons extend to blood vessels, the heart, and visceral organs. The anatomical sequence is a spinal preganglionic neuron, a peripheral ganglion, and a postganglionic axon reaching the target tissue. Preganglionic sympathetic neurons release acetylcholine in the ganglia; most postganglionic sympathetic neurons instead release norepinephrine near their targets. Sympathetic innervation is not invariably noradrenergic: the postganglionic fibers supplying thermoregulatory eccrine sweat glands are cholinergic. This exception separates classification by anatomical pathway from classification by transmitter. (ncbi.nlm.nih.gov)

The adrenal medulla provides a different peripheral arrangement. Its chromaffin cells receive direct cholinergic input from sympathetic preganglionic fibers, rather than being reached through an ordinary postganglionic axon. They release catecholamines—predominantly epinephrine, together with a smaller amount of norepinephrine—into the circulation. Thus, adrenal norepinephrine acts as a circulating hormone, whereas norepinephrine discharged by sympathetic nerve endings acts locally as a neurotransmitter. The distinction is anatomical as well as functional: chromaffin-cell secretion enters the blood and can reach distant tissues, while neuronal release occurs near the cells innervated by the releasing axon. (ncbi.nlm.nih.gov)

Release, reuptake, and metabolic clearance

At noradrenergic nerve endings, an arriving action potential depolarizes the terminal membrane and opens voltage-gated calcium channels. Calcium entry triggers fusion of transmitter-containing vesicles with the cell membrane, releasing norepinephrine by exocytosis into the extracellular space near target cells. Release therefore transfers stored transmitter outside the neuron rather than requiring its synthesis with every impulse. Adrenal chromaffin cells use a related calcium-dependent mechanism, but their immediate stimulus is acetylcholine released by sympathetic preganglionic nerves. Activation of nicotinic acetylcholine receptors produces depolarization and recruits voltage-dependent calcium channels; calcium entering directly through nicotinic receptors can also contribute to secretion. Experiments on human chromaffin cells by Alberto Pérez-Alvarez and Almudena Albillos in 2007 demonstrated both routes of calcium entry during acetylcholine-evoked exocytosis. (jci.org)

Removal from the extracellular space does not necessarily mean chemical destruction. A major mechanism terminating neuronal norepinephrine signaling is reuptake through the norepinephrine transporter (NET), historically termed uptake 1. This membrane transport system depends on sodium and chloride gradients and returns released transmitter to the neuronal cytoplasm. Once inside, norepinephrine can be repackaged into vesicles by vesicular monoamine transporters for subsequent release, or undergo intracellular metabolism. Reuptake thus both limits extracellular exposure and conserves transmitter. It differs from diffusion away from a release site, which redistributes norepinephrine without itself altering the molecule, and from extraneuronal uptake into neighboring non-neuronal cells, historically called uptake 2. The relative contributions of these routes vary among tissues. (onlinelibrary.wiley.com)

Two major enzymes participate in metabolic disposal: monoamine oxidase (MAO) and catechol-O-methyltransferase (COMT). In sympathetic neurons, mitochondrial MAO initiates oxidative deamination of cytoplasmic norepinephrine; subsequent reduction of the aldehyde intermediate produces 3,4-dihydroxyphenylglycol (DHPG). This pathway handles both recaptured transmitter and norepinephrine that leaks from storage vesicles into the cytoplasm. DHPG can leave the neuron and undergo extraneuronal O-methylation by COMT to form 3-methoxy-4-hydroxyphenylglycol (MHPG). Alternatively, COMT acts directly on norepinephrine in extraneuronal tissues to produce normetanephrine, which can undergo further deamination and metabolism. These are interconnected pathways, not a single obligatory sequence in which every molecule encounters the enzymes in the same order. (jci.org)

Vanillylmandelic acid (VMA) is a major terminal urinary product of norepinephrine metabolism, with the liver integrating several precursor pathways. In a 1996 human study, Graeme Eisenhofer and colleagues compared regional plasma concentrations across mesenteric organs, liver, and kidneys. Higher VMA concentrations in hepatic outflow than inflow supported substantial hepatic formation from norepinephrine and its glycol metabolites, including DHPG and MHPG. Urinary VMA therefore reflects processing across multiple tissues rather than degradation exclusively at nerve endings. (pubmed.ncbi.nlm.nih.gov)

Circulating norepinephrine is cleared rapidly, but its plasma half-life is not the duration of signaling at an individual neuroeffector junction. Human radiotracer experiments reported a rapid plasma-disappearance phase with a half-time of approximately $2.0 \pm 0.4$ minutes, followed by a slower phase. Plasma concentration reflects the balance between entry into blood—often termed spillover from sympathetic nerves—and removal by tissue uptake and metabolism. Much released transmitter is recaptured locally before reaching the circulation. Consequently, identical blood concentrations can accompany different release or clearance rates, and a blood measurement does not directly specify the concentration, timing, or receptor exposure at a particular nerve–target interface. (pubmed.ncbi.nlm.nih.gov)

Adrenergic receptors and intracellular signaling

Norepinephrine acts through adrenergic receptors, or adrenoceptors, comprising nine recognized subtypes: $\alpha_{1A}$, $\alpha_{1B}$, and $\alpha_{1D}$; $\alpha_{2A}$, $\alpha_{2B}$, and $\alpha_{2C}$; and $\beta_1$, $\beta_2$, and $\beta_3$. All are G-protein-coupled receptors with seven membrane-spanning segments, not ligand-gated ion channels. Binding changes receptor conformation and activates intracellular heterotrimeric G proteins, which regulate enzymes and channels. Thus, norepinephrine modifies cellular activity through intermediary signaling mechanisms rather than by opening a pore in the receptor itself. The canonical coupling patterns are $\alpha_1$–$G_{q/11}$, $\alpha_2$–$G_{i/o}$, and $\beta$–$G_s$, although these are predominant pathways rather than exclusive connections. (bpspubs.onlinelibrary.wiley.com)

Activation of $\alpha_1$ receptors stimulates phospholipase C through $G_{q/11}$. This enzyme cleaves the membrane phospholipid phosphatidylinositol 4,5-bisphosphate into inositol 1,4,5-trisphosphate (IP₃) and diacylglycerol. IP₃ releases calcium from intracellular stores, while diacylglycerol participates in protein kinase C activation. These signals alter phosphorylation, calcium availability, and cellular responsiveness. Increased cytosolic calcium can support smooth-muscle contraction, but the response depends on the cell’s downstream machinery; $\alpha_1$ activation is not synonymous with a single physiological effect. (bpspubs.onlinelibrary.wiley.com)

The $\alpha_2$ family predominantly activates $G_{i/o}$, with $G_{\alpha i}$ inhibiting adenylyl cyclase and reducing cyclic AMP (cAMP) formation. A separate branch involves G-protein $\beta\gamma$ subunits, which can inhibit voltage-gated calcium channels. Experiments in rat sympathetic neurons identified $\beta\gamma$ dimers associated with $G_o$ and $G_i$ as mediators of norepinephrine-induced inhibition of N-type calcium currents. At noradrenergic terminals, presynaptic $\alpha_2$ autoreceptors detect released norepinephrine and suppress further transmitter release, providing negative feedback. This autoreceptor function must be distinguished from postsynaptic $\alpha_2$ actions: receptors on target neurons regulate those neurons’ own signaling and excitability rather than directly sensing their own norepinephrine output. (bpspubs.onlinelibrary.wiley.com)

The three $\beta$ subtypes predominantly stimulate adenylyl cyclase through $G_s$, increasing cAMP and activating cAMP-dependent protein kinase A. The resulting phosphorylation changes depend on the proteins available in the cell, rather than following a universal “excitatory” program. Additional coupling further complicates this scheme: $\beta_3$ receptors can activate $G_i$, reduce cAMP in some experimental systems, and engage nitric-oxide-dependent signaling. Their documented expression in human bladder smooth muscle and adipose tissue illustrates why receptor location and cellular signaling machinery must be considered together. (bpspubs.onlinelibrary.wiley.com)

Norepinephrine activates both $\alpha$ families and all three $\beta$ subtypes, but has greater activity at $\beta_1$ than at $\beta_2$ receptors. The IUPHAR/BPS database reports human-receptor binding values of $pK_i=5.5–6.0$ for $\beta_1$, compared with $4.6–5.4$ for $\beta_2$, where $pK_i=-\log_{10}(K_i/\mathrm{mol\,L^{-1}})$; higher values indicate greater affinity. These assay-dependent ranges should not be treated as fixed tissue-response thresholds. Epinephrine is more potent than norepinephrine at $\beta_2$, whereas norepinephrine remains an effective endogenous $\beta_3$ agonist. Consequently, an organ’s response reflects its receptor population and local signaling context, not simply the presence of norepinephrine or an absolute division into “alpha-stimulating” and “beta-stimulating” effects. (guidetopharmacology.org)

Peripheral physiological functions

Norepinephrine contracts vascular smooth muscle, principally through α₁-adrenoceptors, increasing resistance to blood flow and supporting arterial blood pressure. α₁ signaling increases intracellular calcium availability and activates the contractile apparatus; narrowing small arteries and arterioles raises systemic vascular resistance, while venous constriction can increase venous return to the heart. These actions allow the sympathetic nervous system to adjust vascular tone rather than simply switch vessels between constricted and relaxed states. Norepinephrine differs importantly from epinephrine in having weaker activity at β₂-adrenoceptors: its vascular effects therefore lack the same degree of opposing β₂-mediated vasodilation. (pmc.ncbi.nlm.nih.gov)

In the heart, norepinephrine activates β₁-adrenoceptors, increasing myocardial contractile force and directly accelerating sinoatrial pacemaker activity. These direct effects must be distinguished from the response of an intact circulation. When norepinephrine raises arterial pressure, the baroreceptor reflex increases vagal activity and can slow the heart despite continuing adrenergic stimulation. Consequently, a rise in blood pressure need not be accompanied by tachycardia, and cardiac output does not necessarily increase: its net change depends on contractility, heart rate, venous return, and the resistance against which the ventricles eject blood. Reflex slowing is especially evident when circulating norepinephrine is increased experimentally or pharmacologically; it does not mean that norepinephrine directly inhibits cardiac pacemaker cells. (dailymed.nlm.nih.gov)

In the gastrointestinal tract, noradrenergic signaling generally suppresses propulsive activity, partly by activating presynaptic α₂-adrenoceptors on enteric cholinergic neurons and reducing acetylcholine release. Experiments in α₂A-adrenoceptor-deficient mice demonstrated the importance of this mechanism for inhibition of neurogenic contractions and gastrointestinal transit. Direct effects on intestinal muscle are more heterogeneous than this overall inhibitory pattern suggests. A 2020 study of human colonic tissue found that norepinephrine could either inhibit or enhance contractions through different α₁-adrenoceptor subtypes and cellular targets. Thus, reduced gastrointestinal propulsion cannot be equated with uniform relaxation of every smooth-muscle component. (pubmed.ncbi.nlm.nih.gov)

In the lower urinary tract, sympathetic norepinephrine favors urine storage through complementary actions: β₃-adrenoceptor activation relaxes the bladder detrusor, whereas α₁-mediated contraction of the bladder outlet increases resistance to urine flow. In 1999, studies by Masaki Takeda and colleagues and by Yasuhiko Igawa and colleagues combined receptor-expression measurements with isolated human detrusor experiments to establish a functional role for β₃-adrenoceptors in bladder relaxation. In the kidney, norepinephrine also stimulates renin secretion through β₁-adrenoceptors on juxtaglomerular granular cells, linking renal sympathetic activity to hormonal regulation of blood pressure rather than merely to renal vasoconstriction. (pubmed.ncbi.nlm.nih.gov)

Norepinephrine contributes to energy mobilization by stimulating adipose-tissue lipolysis, releasing fatty acids and glycerol. β-adrenoceptor stimulation promotes this process, while adipocyte α₂-adrenoceptors oppose it; the net response varies among fat depots. Human adipocyte experiments have demonstrated stronger norepinephrine-induced lipolysis in visceral than in subcutaneous fat under the conditions studied. Its metabolic actions overlap with, but are not identical to, those of circulating epinephrine. For example, in a 2001 crossover experiment involving seven fit men exercising at moderate intensity, norepinephrine infusion increased glucose production to $7.55\pm0.68$, compared with $4.40\pm0.44\ \mathrm{mg\,kg^{-1}\,min^{-1}}$ during control exercise, without a corresponding between-condition difference in blood glucose concentration. (pubmed.ncbi.nlm.nih.gov)

Cold-induced norepinephrine release also activates brown adipose thermogenesis. Adrenergic stimulation increases fuel mobilization and mitochondrial respiration, while uncoupling protein 1 permits energy to be dissipated as heat rather than conserved through ATP synthesis. Receptor contributions differ between species: β₃-mediated thermogenesis is prominent in rodent brown fat, whereas a 2020 study of human brown adipocytes identified an important β₂-mediated response using selective pharmacological agents and receptor knockdown. Norepinephrine’s relatively weak β₂ activity therefore does not imply that β₂ signaling is physiologically irrelevant in every peripheral tissue. (pubmed.ncbi.nlm.nih.gov)

Central functions in arousal, attention, and memory

Norepinephrine regulates wakefulness through state-dependent modulation rather than uniform excitation of the brain. Noradrenergic neurons of the locus coeruleus generally fire most actively during waking, less during non-rapid-eye-movement (NREM) sleep, and minimally during rapid-eye-movement (REM) sleep. In 2010, Matthew Carter and colleagues demonstrated that optogenetic activation of these neurons in mice could trigger sleep-to-wake transitions, establishing a causal contribution to arousal. The temporal pattern matters: sustained stimulation at frequencies of 5 Hz or above could instead produce reversible behavioral arrest, rather than progressively increasing alertness. (pmc.ncbi.nlm.nih.gov) Norepinephrine also fluctuates within sleep. A 2022 mouse study found that peaks in slow extracellular norepinephrine oscillations accompanied brief arousals, whereas falling concentrations favored sleep spindles—bursts of synchronized electrical activity associated with memory processing. (nature.com)

In attention, noradrenergic activity is sensitive to behavioral relevance, not merely the physical presence of a stimulus. Gary Aston-Jones and colleagues reported in 1994 that locus-coeruleus neurons in monkeys responded preferentially to attended target cues in a visual vigilance task. The phasic response began, on average, approximately 91 milliseconds after the cue and about 200 milliseconds before the animal released a lever. Responses diminished during prolonged task performance alongside declining accuracy. These observations connect noradrenergic signaling with the selection of behaviorally significant information, rather than indiscriminate sensory activation. (pmc.ncbi.nlm.nih.gov) Experiments comparing tonic and burst-like locus-coeruleus stimulation further show that release patterns produce different changes in cortical activity and connectivity; norepinephrine therefore changes how networks process information, rather than simply switching them on. (nature.com)

A specific mechanism operates in the prefrontal cortex during working memory, the temporary maintenance of information needed to guide behavior. In 2007, Min Wang and colleagues showed that stimulation of postsynaptic $\alpha_{2A}$-adrenergic receptors reduced cyclic AMP signaling and closed hyperpolarization-activated cyclic-nucleotide-gated (HCN) ion channels. This strengthened functional connections between prefrontal neurons and increased spatially selective firing during the delay period of a memory task. Thus, inhibition of an intracellular signaling pathway can strengthen network activity. (pubmed.ncbi.nlm.nih.gov) The effect is receptor-dependent: experimental stimulation of prefrontal $\alpha_1$ receptors impaired spatial working-memory performance in rats. Noradrenergic enhancement of cognition consequently cannot be described as a simple relationship in which more transmitter always produces better performance. (pubmed.ncbi.nlm.nih.gov)

Longer-lasting memory effects involve interactions among the amygdala, hippocampus, and cortex. In experiments reported by Erika Atucha and colleagues in 2017, norepinephrine administered into the basolateral amygdala immediately after avoidance-discrimination training helped rats retain context-specific memory at a remote test. Hippocampal inactivation during testing abolished this specificity, indicating continued dependence on hippocampal processing. The treatment also altered the time course of memory-related gene expression and DNA methylation in the hippocampus and anterior cingulate cortex. These findings identify a mechanism through which amygdala noradrenergic signaling can influence plasticity and the longer-term organization of memories elsewhere, rather than serving as their sole storage site. (pmc.ncbi.nlm.nih.gov)

Central stress signaling recruits these arousal and memory circuits. Experiments in rats showed that corticotropin-releasing factor delivered into the locus coeruleus increased behavioral activation, linking a stress-related peptide to noradrenergic control of behavioral state. These are central circuit effects, distinct from norepinephrine’s direct actions on peripheral organs. (jneurosci.org) Its modulation of pain is likewise pathway-specific. Stefan Hirschberg and colleagues demonstrated in 2017 that activating spinal-projecting locus-coeruleus neurons in rats produced $\alpha_2$-receptor-mediated antinociception and reduced neuropathic pain-related behavior. Activating prefrontal-projecting neurons instead produced aversion and anxiety-like behavior and increased signs of spontaneous pain after nerve injury. Descending noradrenergic signaling can therefore suppress nociceptive processing in the spinal cord, while other noradrenergic circuits influence pain’s affective and behavioral dimensions differently. (elifesciences.org)

Measurement and clinical interpretation

Norepinephrine can be measured directly in plasma or urine, usually alongside epinephrine and dopamine. These catecholamine assays differ from tests for metanephrines, which measure metabolites rather than the parent transmitters: normetanephrine is derived from norepinephrine, whereas metanephrine is derived from epinephrine. Plasma free metanephrines are unconjugated metabolites; urinary fractionated metanephrines report normetanephrine and metanephrine separately, commonly in a 24-hour collection. Chromatographic methods with electrochemical detection or tandem mass spectrometry distinguish these compounds analytically. Thus, a request for “norepinephrine testing” does not identify a single interchangeable blood test. (nichd.nih.gov)

A major application is biochemical investigation of pheochromocytoma, an adrenal chromaffin-cell tumor, and paraganglioma, a related extra-adrenal tumor. Catecholamine production varies among tumors; some produce predominantly norepinephrine, while others produce different combinations or little measurable catecholamine. Metanephrines are useful because their formation within tumor cells can continue independently of episodic catecholamine release. In a 2002 study by Jacques W. M. Lenders and colleagues, sensitivity was 99% for plasma free metanephrines and 97% for urinary fractionated metanephrines, compared with 84% for plasma catecholamines and 86% for urinary catecholamines. These figures describe the study population and assays, not universal performance guarantees. The Endocrine Society’s 2014 guideline identified plasma free or urinary fractionated metanephrines as initial biochemical tests for these tumors. (support.endocrine.org)

Posture and sampling conditions materially affect interpretation. Moving from recumbency to an upright position activates sympathetic outflow and can increase norepinephrine and normetanephrine; physical exertion, emotional stress, and acute illness can also elevate results without a tumor. The 2014 guideline specified at least 30 minutes of recumbency before supine plasma metanephrine sampling, with reference intervals established under corresponding conditions. Age, assay method, specimen type, collection completeness, and laboratory-specific reference intervals also matter. A small isolated elevation therefore has a different evidential meaning from a pronounced, reproducible elevation in an appropriate clinical setting; neither an elevated norepinephrine concentration nor a positive screening result alone establishes tumor diagnosis. (academic.oup.com)

Medications introduce both physiological and analytical confounding. Norepinephrine-reuptake inhibitors, including tricyclic antidepressants and serotonin–norepinephrine reuptake inhibitors, can raise normetanephrine by altering transmitter handling rather than through tumor secretion. A study published online in 2023 documented increased false-positive results associated with these drugs. Other substances interfere with particular measurement methods: acetaminophen, for example, can affect some liquid-chromatographic assays using electrochemical detection. Interpretation therefore depends on the medication exposure and analytical platform, not merely on whether a reported value exceeds an upper limit. (pubmed.ncbi.nlm.nih.gov)

Peripheral concentrations are not direct measurements of brain neurotransmission. Plasma norepinephrine reflects the balance between entry into blood—including spillover from peripheral sympathetic nerves—and removal from circulation. Murray Esler and colleagues demonstrated in human kinetic studies that clearance and regional differences complicate its use even as an index of peripheral sympathetic activity. A blood or urine result consequently cannot quantify norepinephrine at particular central synapses or establish a psychiatric disorder through an inferred transmitter “excess” or “deficiency.” For example, depression diagnosis rests on symptoms, duration, functional effects, and assessment of alternative causes, rather than on a peripheral norepinephrine concentration. (pubmed.ncbi.nlm.nih.gov)

Norepinephrine as a medicine

Pharmaceutical norepinephrine is an intravenous catecholamine vasopressor, a medicine that raises blood pressure principally by constricting blood vessels. United States prescribing information identifies its indication as raising blood pressure in adults with severe, acute hypotension and records initial U.S. approval in 1950. Its pressor action develops rapidly during infusion and subsides within approximately 1–2 minutes after infusion stops, making its circulatory effects closely dependent on continued administration. This medicinal use supplies norepinephrine directly to the circulation rather than modifying its release from nerve endings. (dailymed.nlm.nih.gov)

The principal hemodynamic action is α-adrenergic vasoconstriction, which increases systemic vascular resistance; β-adrenergic cardiac stimulation also increases contractile force. These actions do not imply a uniform increase in heart rate or cardiac output. The rise in arterial pressure activates reflex vagal activity, which can slow the heart despite direct cardiac stimulation, while cardiac output may remain unchanged or decrease. (dailymed.nlm.nih.gov) In severely hypotensive septic patients, increased cardiac filling and contractility can instead increase output. In a 2010 study by Olfa Hamzaoui and colleagues involving 105 patients with septic shock who had already received volume resuscitation, norepinephrine initiation or escalation increased mean arterial pressure from $54 \pm 8$ to $76 \pm 9$ mmHg and cardiac index—cardiac output indexed to body surface area—from $3.2 \pm 1.0$ to $3.6 \pm 1.1$ L/min/m². These observations illustrate why a pressure response and a flow response are distinct measurements. (pubmed.ncbi.nlm.nih.gov)

Injectable preparations contain norepinephrine bitartrate, but labeled strengths commonly express the equivalent amount of norepinephrine base rather than the total mass of salt. One concentrate contains 1 mg of norepinephrine base per millilitre, equivalent to 1.89 mg of norepinephrine bitartrate on an anhydrous basis, and is supplied in 4-mL single-dose vials requiring dilution before infusion. (dailymed.nlm.nih.gov) Premixed products are distinct formulations: examples include ready-to-administer 250-mL bags containing 4, 8, or 16 mg of norepinephrine base equivalent in 0.9% sodium chloride, corresponding to 16, 32, or 64 micrograms/mL. These bags require no further dilution. Thus, salt mass, base-equivalent drug content, total container content, and solution concentration describe different aspects of a preparation. (dailymed.nlm.nih.gov)

Excessive vasoconstriction can produce ischemia even when the measured arterial pressure appears normal. Product labeling specifically describes severe peripheral and visceral vasoconstriction in patients whose hypotension reflects inadequate circulating blood volume, with reduced renal perfusion, diminished urine output, tissue hypoxia, lactic acidosis, and reduced systemic blood flow. Gangrene has occurred, particularly in association with occlusive or thrombotic vascular disease or prolonged or high-dose infusions. Restoration of blood pressure therefore does not itself establish adequate tissue perfusion. (dailymed.nlm.nih.gov)

Extravasation—the leakage of infused solution outside the vein—can cause intense local vasoconstriction, tissue necrosis, and sloughing. Other recognized hazards include hypertension, reflex bradycardia, and cardiac arrhythmias; the arrhythmia risk is particularly noted in the presence of hypoxia or elevated carbon dioxide. Abrupt cessation can cause marked hypotension as the short-lived pressor effect disappears. (dailymed.nlm.nih.gov)

Drugs that modify noradrenergic transmission

Drugs can modify noradrenergic transmission by changing transmitter synthesis, vesicular storage, release, reuptake, or metabolism, or by acting directly at adrenergic receptors. These targets are pharmacologically distinct: reducing transmitter production is not equivalent to blocking its receptors. Metyrosine inhibits tyrosine hydroxylase, the enzyme that converts tyrosine to L-DOPA, thereby reducing synthesis of norepinephrine and other catecholamines. Reserpine instead inhibits vesicular monoamine transport, preventing efficient packaging into secretory vesicles and depleting releasable stores. A 1993 study by Shimon Schuldiner, Yongjian Liu, and Robert Edwards demonstrated its high-affinity interaction with a cloned vesicular transporter. Neither mechanism is specific to norepinephrine alone. (dailymed.nlm.nih.gov)

Release and metabolic breakdown provide additional targets. Amphetamines increase extracellular norepinephrine and dopamine through actions that include promoting release and inhibiting reuptake; their effects therefore differ from those of a drug that only blocks transmitter clearance. Phenelzine acts at a later biochemical step by inhibiting monoamine oxidase, which participates in the breakdown of norepinephrine and other monoamines. Its effects extend beyond noradrenergic transmission. This also creates important pharmacological interactions: phenelzine labeling identifies potentially dangerous combinations with sympathomimetic drugs, including amphetamines, because excessive monoaminergic activity can produce severe cardiovascular effects. (dailymed.nlm.nih.gov)

Inhibition of the norepinephrine transporter (NET) reduces presynaptic recapture and prolongs extracellular transmitter availability. Atomoxetine is a selective NET inhibitor used for attention-deficit/hyperactivity disorder (ADHD), but transporter selectivity does not mean that its downstream effects involve only one transmitter or occur uniformly throughout the brain. In a 2002 study, Frank P. Bymaster and colleagues found that atomoxetine increased extracellular norepinephrine and dopamine in rat prefrontal cortex without increasing dopamine in the striatum or nucleus accumbens. These regional findings are experimental observations, not direct measurements of its therapeutic mechanism in humans; prescribing information states that the precise mechanism of its clinical benefit remains unknown. (pubmed.ncbi.nlm.nih.gov)

Serotonin–norepinephrine reuptake inhibitors (SNRIs), exemplified by duloxetine, inhibit uptake of both serotonin and norepinephrine. This designation describes transporter actions rather than direct stimulation of adrenergic receptors. Duloxetine has no significant affinity for adrenergic receptors in vitro and does not inhibit monoamine oxidase. Its labeling distinguishes the established reuptake effects from the incompletely understood mechanisms underlying its antidepressant, anxiolytic, and central pain-inhibitory actions. Thus, sharing NET inhibition does not make atomoxetine and duloxetine clinically interchangeable or establish identical effects across neural circuits. (dailymed.nlm.nih.gov)

Direct agonists and antagonists act at adrenergic receptors rather than primarily changing transmitter availability. Phenylephrine activates α1 receptors on vascular smooth muscle, producing vasoconstriction; propranolol is a nonselective β-receptor antagonist. Central receptor activation can instead reduce sympathetic output: guanfacine activates α2A receptors and has approximately 15–20 times greater affinity for this subtype than for α2B or α2C receptors. Its central actions reduce sympathetic impulses to the heart and blood vessels. Consequently, “adrenergic agonist” does not necessarily mean a drug that increases every sympathetic response. (dailymed.nlm.nih.gov)

A demonstrated drug target must also be distinguished from an explanation of disease causation. NET inhibition establishes a pharmacological action, not a pre-existing norepinephrine deficiency in an individual with ADHD or depression. Likewise, benefit from receptor activation or blockade does not by itself identify a disorder as a simple transmitter excess or shortage. The distinction is reflected in prescribing information that identifies molecular targets while leaving therapeutic mechanisms unresolved. Clinical timing adds another separation: the National Institute of Mental Health reports that antidepressants generally require 4–8 weeks to work, with some symptoms improving before mood, rather than describing recovery as an immediate consequence of altered transmitter availability. (dailymed.nlm.nih.gov)

Discovery and development of the transmitter concept

In 1946, Ulf von Euler identified norepinephrine as the principal neurotransmitter of mammalian sympathetic adrenergic nerves, rather than discovering a previously unknown chemical. Friedrich Stolz had synthesized the substance in 1904. That same year, Thomas Renton Elliott had proposed that sympathetic nerves might act by releasing adrenaline, now also called epinephrine. Von Euler’s advance was to distinguish the substance in extracts of sympathetic nerves, including splenic nerves, from epinephrine through its pharmacological actions and chemical characteristics. His investigations, published in 1946 and extended in 1948, established that the relevant transmitter was epinephrine’s nonmethylated counterpart, noradrenaline. (nobelprize.org)

Evidence from denervation helped connect the chemical identification to a neuronal function. When sympathetic nerves supplying the heart and certain other organs were cut and subsequently degenerated, tissue norepinephrine content fell markedly or disappeared; when cardiac nerves regenerated, it returned toward normal. These observations supported the conclusion that the substance belonged to the nerves within an organ, rather than simply to the organ’s other cells. They also made tissue norepinephrine content a biochemical indicator of sympathetic innervation, complementing anatomical methods then available. (nobelprize.org)

Von Euler’s subsequent work with Nils-Åke Hillarp located norepinephrine storage within intracellular nerve granules. The 1970 Nobel presentation described these particles as approximately one ten-thousandth of a millimetre, or 100 nanometres, in diameter. Demonstrating a particulate storage compartment shifted the transmitter concept beyond identifying an active substance in tissue extracts: norepinephrine was held in specialized structures within nerve fibres, not merely dispersed throughout the cell. The granules provided an experimentally accessible basis for investigating how a potent chemical messenger could be retained before release and made available for repeated signaling. (nobelprize.org)

Julius Axelrod investigated what happened after norepinephrine left the nerve terminal. His studies established enzymatic O-methylation as a route of catecholamine metabolism and characterized catechol-O-methyltransferase, which uses S-adenosylmethionine as its methyl donor. More consequential for understanding signal termination was the demonstration of neuronal reuptake. In experiments described in his Nobel lecture, injected tritium-labelled norepinephrine accumulated in sympathetically innervated tissues; pretreatment with cocaine markedly reduced tissue accumulation and increased labelled norepinephrine in plasma. Uptake blockade therefore explained how cocaine could enhance norepinephrine’s effects without acting simply as an additional transmitter. These findings distinguished removal from the receptor environment from chemical destruction: released norepinephrine could be recaptured by nerve terminals and returned to storage, rather than necessarily being metabolized immediately. (nobelprize.org)

The 1970 Nobel Prize in Physiology or Medicine was awarded jointly to von Euler, Axelrod, and Bernard Katz for discoveries concerning chemical transmitters in nerve terminals and their storage, release, and inactivation. Their contributions were complementary, not identical. Von Euler identified the sympathetic transmitter and investigated its granular storage; Axelrod elucidated mechanisms governing its inactivation, especially reuptake. Katz’s principal experimental system was acetylcholine transmission at the nerve–muscle junction, where miniature end-plate potentials revealed that transmitter release occurred in discrete quanta. His award therefore recognized a general mechanism of chemical transmission, not the identification of norepinephrine itself. (nobelprize.org)

References

1. Norepinephrine | C8H11NO3 | CID 439260 - PubChempubchem.ncbi.nlm.nih.gov
2. R and S — IUPAC Recommendations 1996iupac.qmul.ac.uk
3. Dopamine | C8H11NO2 | CID 681 - PubChempubchem.ncbi.nlm.nih.gov
4. Epinephrine | C9H13NO3 | CID 5816 - PubChempubchem.ncbi.nlm.nih.gov
5. DailyMed — Norepinephrine bitartrate injection, solution, concentratedailymed.nlm.nih.gov
6. A Biochemical and Functional Protein Complex Involving Dopamine Synthesis and Transport into Synaptic Vesiclespmc.ncbi.nlm.nih.gov
7. Direct binding of GTP cyclohydrolase and tyrosine hydroxylase: regulatory interactions between key enzymes in dopamine biosynthesispubmed.ncbi.nlm.nih.gov
8. Tyrosine hydroxylase activity is regulated by two distinct dopamine-binding sitespubmed.ncbi.nlm.nih.gov
9. Molecular basis of vesicular monoamine transport and neurological drug interactionspmc.ncbi.nlm.nih.gov
10. Distinct pharmacological properties and distribution in neurons and endocrine cells of two isoforms of the human vesicular monoamine transporterpubmed.ncbi.nlm.nih.gov
11. Correlation of copper valency with product formation in single turnovers of dopamine beta-monooxygenasepubmed.ncbi.nlm.nih.gov
12. The in situ kinetics of dopamine beta-hydroxylase in bovine adrenomedullary chromaffin cells. Intravesicular compartmentation reduces apparent affinity for the cofactor ascorbatepubmed.ncbi.nlm.nih.gov
13. Adrenaline synthesis: control by the pituitary gland and adrenal glucocorticoidspubmed.ncbi.nlm.nih.gov
14. Hormonal control of rat adrenal phenylethanolamine N-methyltransferase. Enzyme activity, the final critical pathwaypubmed.ncbi.nlm.nih.gov
15. Physiology, Noradrenergic Synapsencbi.nlm.nih.gov
16. Efferent connections of the A1 noradrenergic cell group: a DBH immunohistochemical and PHA-L anterograde tracing studypubmed.ncbi.nlm.nih.gov
17. Catecholaminergic projections from the solitary tract nucleus to the perifornical hypothalamuspubmed.ncbi.nlm.nih.gov
18. Efferent projections of nucleus locus coeruleus: topographic organization of cells of origin demonstrated by three-dimensional reconstructionpubmed.ncbi.nlm.nih.gov
19. Spinal projections of the A5, A6 (locus coeruleus), and A7 noradrenergic cell groups in ratspubmed.ncbi.nlm.nih.gov
20. Spinal projections of the A5, A6 (locus coeruleus), and A7 noradrenergic cell groups in ratspmc.ncbi.nlm.nih.gov
21. Anatomy, Autonomic Nervous Systemncbi.nlm.nih.gov
22. Neurotransmission in the Visceral Motor Systemncbi.nlm.nih.gov
23. Evaluation and Management of Autonomic Dysreflexia and Other Autonomic Dysfunctions: Preventing the Highs and Lows: Management of Blood Pressure, Sweating, and Temperature Dysfunctionpmc.ncbi.nlm.nih.gov
24. The adrenal glandncbi.nlm.nih.gov
25. Plasma Dihydroxyphenylglycol and the Intraneuronal Disposition of Norepinephrine in Humansjci.org
26. Key role of the nicotinic receptor in neurotransmitter exocytosis in human chromaffin cellspubmed.ncbi.nlm.nih.gov
27. Julius Axelrod - Nobel Lecturenobelprize.org
28. Mesenteric organ production, hepatic metabolism, and renal elimination of norepinephrine and its metabolites in humanspubmed.ncbi.nlm.nih.gov
29. Effect of norepinephrine uptake blockers on norepinephrine kineticspubmed.ncbi.nlm.nih.gov
30. Biochemical quantification of sympathetic nervous activity in humans using radiotracer methodology: fallibility of plasma noradrenaline measurementspubmed.ncbi.nlm.nih.gov
31. (-)-noradrenaline — IUPHAR/BPS Guide to PHARMACOLOGYguidetopharmacology.org
32. betagamma dimers derived from Go and Gi proteins contribute different components of adrenergic inhibition of Ca2+ channels in rat sympathetic neuronespubmed.ncbi.nlm.nih.gov
33. Direct interaction of Gβγ with a C-terminal Gβγ-binding domain of the Ca2+ channel α1 subunit is responsible for channel inhibition by G protein-coupled receptorspmc.ncbi.nlm.nih.gov
34. alpha2-Adrenergic receptor-mediated modulation of calcium current in neocortical pyramidal neuronspubmed.ncbi.nlm.nih.gov
35. β3-adrenoceptor — IUPHAR/BPS Guide to PHARMACOLOGYguidetopharmacology.org
36. The Concise Guide to PHARMACOLOGY 2023/24: G protein-coupled receptorspmc.ncbi.nlm.nih.gov
37. DailyMed - NOREPINEPHRINE- norepinephrine bitartrate solutiondailymed.nlm.nih.gov
38. Alpha 2-adrenoceptors in the enteric nervous system: a study in alpha 2A-adrenoceptor-deficient micepubmed.ncbi.nlm.nih.gov
39. Norepinephrine Has Dual Effects on Human Colonic Contractions Through Distinct Subtypes of Alpha 1 Adrenoceptorspmc.ncbi.nlm.nih.gov
40. Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methodspubmed.ncbi.nlm.nih.gov
41. Functional and molecular biological evidence for a possible beta3-adrenoceptor in the human detrusor musclepubmed.ncbi.nlm.nih.gov
42. Distribution of alpha- and beta-adrenoceptors in human urinary bladderpubmed.ncbi.nlm.nih.gov
43. The role of beta-1-adrenoceptors in the renin release response to graded renal sympathetic nerve stimulationpubmed.ncbi.nlm.nih.gov
44. Noradrenaline-induced lipolysis in isolated mesenteric, omental and subcutaneous adipocytes from obese subjectspubmed.ncbi.nlm.nih.gov
45. Pharmacological Characterizations of Adrenergic Receptors in Human Adipocytespmc.ncbi.nlm.nih.gov
46. Norepinephrine infusion during moderate-intensity exercise increases glucose production and uptakepubmed.ncbi.nlm.nih.gov
47. Coexisting beta-adrenoceptor subtypes: significance for thermogenic process in brown fat cellspubmed.ncbi.nlm.nih.gov
48. Tuning arousal with optogenetic modulation of locus coeruleus neuronspmc.ncbi.nlm.nih.gov
49. Memory-enhancing properties of sleep depend on the oscillatory amplitude of norepinephrinenature.com
50. Locus coeruleus neurons in monkey are selectively activated by attended cues in a vigilance taskpmc.ncbi.nlm.nih.gov
51. Tonic and burst-like locus coeruleus stimulation distinctly shift network activity across the cortical hierarchynature.com
52. Alpha2A-adrenoceptors strengthen working memory networks by inhibiting cAMP-HCN channel signaling in prefrontal cortexpubmed.ncbi.nlm.nih.gov
53. Alpha-1 noradrenergic receptor stimulation impairs prefrontal cortical cognitive functionpubmed.ncbi.nlm.nih.gov
54. Noradrenergic activation of the basolateral amygdala maintains hippocampus-dependent accuracy of remote memorypmc.ncbi.nlm.nih.gov
55. How do health care providers diagnose pheochromocytoma?nichd.nih.gov
56. New advances in the biochemical diagnosis of pheochromocytoma: moving beyond catecholaminespubmed.ncbi.nlm.nih.gov
57. Biochemical diagnosis of pheochromocytoma: which test is best?pubmed.ncbi.nlm.nih.gov
58. False-positive results for pheochromocytoma associated with norepinephrine reuptake blockadepubmed.ncbi.nlm.nih.gov
59. Pheochromocytoma and Paraganglioma: An Endocrine Society Clinical Practice Guidelinesoched.cl
60. Measurement of total and organ-specific norepinephrine kinetics in humanspubmed.ncbi.nlm.nih.gov
61. Depression — National Institute of Mental Healthnimh.nih.gov
62. DailyMed — Norepinephrine bitartrate injection, solution, concentratedailymed.nlm.nih.gov
63. Early administration of norepinephrine increases cardiac preload and cardiac output in septic patients with life-threatening hypotensionpubmed.ncbi.nlm.nih.gov
64. DailyMed — Norepinephrine bitartrate in sodium chloride injection, solutiondailymed.nlm.nih.gov
65. DailyMed — METYROSINE capsuledailymed.nlm.nih.gov
66. Reserpine binding to a vesicular amine transporter expressed in Chinese hamster ovary fibroblastspubmed.ncbi.nlm.nih.gov
67. Amphetamine mixed salts extended-release prescribing informationdailymed.nlm.nih.gov
68. DailyMed — NARDIL, phenelzine sulfate tabletdailymed.nlm.nih.gov
69. PHENELZINE SULFATE TABLETS, USP — prescribing informationdailymed.nlm.nih.gov
70. Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorderpubmed.ncbi.nlm.nih.gov
71. DailyMed — ATOMOXETINE HYDROCHLORIDE capsuledailymed.nlm.nih.gov
72. DailyMed — DULOXETINE, duloxetine hydrochloride capsule, delayed releasedailymed.nlm.nih.gov
73. DailyMed — PHENYLEPHRINE HYDROCHLORIDE injection, solutiondailymed.nlm.nih.gov
74. DailyMed — PROPRANOLOL HYDROCHLORIDE tabletdailymed.nlm.nih.gov
75. DailyMed — GUANFACINE tablet, extended releasedailymed.nlm.nih.gov
76. Mental Health Medications — National Institute of Mental Healthnimh.nih.gov
77. U. S. von Euler — Adrenergic Neurotransmitter Functions: Nobel Lecturenobelprize.org
78. The Nobel Prize in Physiology or Medicine 1970 — Award Ceremony Speechnobelprize.org
79. The Nobel Prize in Physiology or Medicine 1970 — Press Releasenobelprize.org